Tenderwize
Retour à la recherche

Open house Arzneimittelrabattverträge Fingolimod in der Wirkstärke 0,25 mg, ATC L04AE01

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Feb 03, 2028 · 523 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Fingolimod in der Wirkstärke 0,25 mg, ATC L04AE01

50/100

Score d'opportunité

PromisingLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

No estimated value or volume is provided. The actual revenue potential is unknown.

Open-house agreements can be automatically superseded by other rebate contracts won in competitive procedures for the s...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive rebate agreements for Fingolimod 0.25 mg (ATC L04AE01)
  • Supply of pharmaceutical product containing active substance Fingolimod 0.25 mg
Afficher le résumé complet

This is an open-house model for non-exclusive rebate agreements (Rabattverträge) for the active substance Fingolimod 0.25 mg (ATC L04AE01) with AOK Bayern. All interested pharmaceutical companies meeting the eligibility criteria can enter into identical, non-negotiable agreements. Contracts run from the earliest start date of 01.04.2026 to 31.03.2028. Joining is possible anytime until 03.02.2028.

Risques

No estimated value or volume is provided. The actual revenue potential is unknown.

Open-house agreements can be automatically superseded by other rebate contracts won in competitive procedures for the s...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit signed contract, signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed self-declaration of reliability.
  • Submission options: paper (two originals) or electronic with qualified electronic signature via DTVP communication area.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Fingolimod in der Wirkstärke 0,25 mg, ATC L04AE01

Open house for non-exclusive rebate agreements on Fingolimod 0.25 mg. Any eligible pharmaceutical company can join. Contracts are identical and non-negotiable. Duration from 01.04.2026 to 31.03.2028.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Mar 2026 - Mar 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 03, 2028

Détails de la procédure

Date de publication
15 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
106909-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30